Where Will Exact Sciences Corporation Be in 5 Years?
Roughly 18 months ago, Exact Sciences (NASDAQ: EXAS) was in rough shape. Cash was getting tight as the company spent aggressively to commercialize its new colon cancer test. Add in some troubling words from a government agency and it is understandable why short-sellers were predicting doom.
Fast-forward to today, Exact Sciences' turnaround has been nothing short of remarkable. Insurance coverage has improved, testing volumes have grown exponentially, and the stock has turned into a monster winner.
But where is this company heading over the next half-decade?
Source: Fool.com
Exact Sciences Aktie
53,20 €
0,32 %
Eine klare Neigung zu Buy-Einschätzungen bei Exact Sciences, ohne Sell-Einschätzungen.
Das Kursziel von 75 € für Exact Sciences weist auf eine Steigerung von über 20% gegenüber dem aktuellen Kurs von 53.2 € hin.
